| scholarly article | Q13442814 |
| P50 | author | Rong He | Q89723283 |
| P2093 | author name string | Ayalew Tefferi | |
| Dong Chen | |||
| David S Viswanatha | |||
| Kaaren K Reichard | |||
| Zheng Jin Tu | |||
| Aref Al-Kali | |||
| Phuong L Nguyen | |||
| Mrinal M Patnaik | |||
| Kebede H Begna | |||
| James D Hoyer | |||
| Jennifer L Oliveira | |||
| Hassan Alkhateeb | |||
| Ming Mai | |||
| Daniel J Devine | |||
| Paul L Ollila | |||
| P2860 | cites work | The role of FLT3 in haematopoietic malignancies | Q24319174 |
| FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? | Q27028163 | ||
| The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia | Q27851416 | ||
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| Prognostic relevance of integrated genetic profiling in acute myeloid leukemia | Q27851726 | ||
| CAP3: A DNA sequence assembly program | Q27860964 | ||
| Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells | Q28138943 | ||
| Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data | Q30577735 | ||
| Amplicon Indel Hunter Is a Novel Bioinformatics Tool to Detect Large Somatic Insertion/Deletion Mutations in Amplicon-Based Next-Generation Sequencing Data. | Q30990644 | ||
| Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study | Q33442949 | ||
| Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data | Q34295164 | ||
| mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells | Q34360637 | ||
| Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology | Q34465792 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| FLT3 in human hematologic malignancies | Q34980355 | ||
| Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397 | Q35909096 | ||
| Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia | Q36356082 | ||
| FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors | Q36362951 | ||
| Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Q37624593 | ||
| Acute myeloid leukemia: 2013 update on risk-stratification and management | Q38092771 | ||
| Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia | Q38241988 | ||
| The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes | Q38481997 | ||
| FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions | Q38675400 | ||
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | Q38712298 | ||
| Detection the Frequency and Characteristics of FLT3 Internal Tandem Duplication Mutations by Capillary Electrophoresis Assay and Next-Generation Sequencing in. | Q38977412 | ||
| Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays | Q39194261 | ||
| Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor | Q39981715 | ||
| Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. | Q40330454 | ||
| Leukemogenic potency of the novel FLT3-N676K mutant | Q40901421 | ||
| Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay | Q42718734 | ||
| Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. | Q44189526 | ||
| Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. | Q53403767 | ||
| Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. | Q54270008 | ||
| Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance | Q58555667 | ||
| Genomic structure of human FLT3: implications for mutational analysis | Q59511715 | ||
| Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia | Q77363619 | ||
| Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations | Q83756555 | ||
| A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations | Q88333728 | ||
| P433 | issue | 3 | |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| P304 | page(s) | 334-343 | |
| P577 | publication date | 2019-08-30 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis | |
| P478 | volume | 33 |
Search more.